Session

IBD (Posters)

RESULTS FROM A LARGE SURVEY EXPLORING PATIENT PREFERENCES FOR TREATMENT ATTRIBUTES IN INFLAMMATORY BOWEL DISEASE ACROSS 7 COUNTRIES IN EUROPE
RESULTS FROM A LARGE SURVEY EXPLORING PATIENT PREFERENCES FOR TREATMENT ATTRIBUTES IN INFLAMMATORY BOWEL DISEASE ACROSS 7 COUNTRIES IN EUROPE

IBD (Posters)  et al.

REAL-LIFE DATA OF TREATMENT PERSISTENCE IN PATIENTS WITH LONG-STANDING CROHN'S DISEASE TREATED WITH BIOLOGICS: RESULTS FROM A CROATIAN TERTIARY CENTER
REAL-LIFE DATA OF TREATMENT PERSISTENCE IN PATIENTS WITH LONG-STANDING CROHN'S DISEASE TREATED WITH BIOLOGICS: RESULTS FROM A CROATIAN TERTIARY CENTER

IBD (Posters)  et al.

A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES
A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

IBD (Posters)  et al.

ADALIMUMAB TROUGH LEVELS DURING INDUCTION ARE NOT ASSOCIATED WITH BIOCHEMICAL REMISSION IN PATIENTS WITH CROHN’S DISEASE
ADALIMUMAB TROUGH LEVELS DURING INDUCTION ARE NOT ASSOCIATED WITH BIOCHEMICAL REMISSION IN PATIENTS WITH CROHN’S DISEASE

IBD (Posters)  et al.

BIFIDOBACTERIUM LONGUM NCC3001 PROMOTES COLONIC TISSUE REPAIR VIA PHOSPHOLIPID METABOLISM AND THE PURINE SALVAGE PATHWAY IN EXPERIMENTAL CHRONIC COLITIS
BIFIDOBACTERIUM LONGUM NCC3001 PROMOTES COLONIC TISSUE REPAIR VIA PHOSPHOLIPID METABOLISM AND THE PURINE SALVAGE PATHWAY IN EXPERIMENTAL CHRONIC COLITIS

IBD (Posters)  et al.

OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

IBD (Posters)  et al.

CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB – A POST HOC ANALYSIS OF SELECTION
CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB – A POST HOC ANALYSIS OF SELECTION

IBD (Posters)  et al.

CAN DYSPLASIA SURVEILLANCE BE BETTER TARGETED BY USING FAECAL CALPROTECTIN MEASUREMENTS IN ULCERATIVE COLITIS?
CAN DYSPLASIA SURVEILLANCE BE BETTER TARGETED BY USING FAECAL CALPROTECTIN MEASUREMENTS IN ULCERATIVE COLITIS?

IBD (Posters)  et al.

COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL REMISSION AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIAL SUBSTUDY RESULTS BY LINE OF TREATMENT AND LOCATION
INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL REMISSION AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIAL SUBSTUDY RESULTS BY LINE OF TREATMENT AND LOCATION

IBD (Posters)  et al.

ASSOCIATION BETWEEN DAILY INTAKE OF ADDED SUGAR AND DISEASE ACTIVITY OR QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
ASSOCIATION BETWEEN DAILY INTAKE OF ADDED SUGAR AND DISEASE ACTIVITY OR QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

PEDIATRIC INFLAMMATORY BOWEL DISEASE AFFECTS THE PATIENTS AND THEIR FAMILIES IN DIFFERENT WAYS DEPENDING ON THE AGE AT DIAGNOSIS
PEDIATRIC INFLAMMATORY BOWEL DISEASE AFFECTS THE PATIENTS AND THEIR FAMILIES IN DIFFERENT WAYS DEPENDING ON THE AGE AT DIAGNOSIS

IBD (Posters)  et al.

REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

IBD (Posters)  et al.

THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THERAPEUTIC REQUIREMENTS AFTER COLECTOMY IN PATIENTS WITH ULCERATIVE COLITIS. RESULTS FROM THE RESERVO STUDY OF GETECCU
INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THERAPEUTIC REQUIREMENTS AFTER COLECTOMY IN PATIENTS WITH ULCERATIVE COLITIS. RESULTS FROM THE RESERVO STUDY OF GETECCU

IBD (Posters)  et al.

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY

IBD (Posters)  et al.

CORRELATION OF MUCOSAL MICROBIAL DIVERSITY WITH MARKER OF INFLAMMATION IN CROHN’S DISEASE
CORRELATION OF MUCOSAL MICROBIAL DIVERSITY WITH MARKER OF INFLAMMATION IN CROHN’S DISEASE

IBD (Posters)  et al.

ACCEPTANCE OF SWITCH, PATIENT SATISFACTION AND ADVERSE EVENTS AFTER SWITCH FROM ADALIMUMAB ORIGINATOR TO BIOSIMILAR SB5 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A REAL-LIFE SETTING
ACCEPTANCE OF SWITCH, PATIENT SATISFACTION AND ADVERSE EVENTS AFTER SWITCH FROM ADALIMUMAB ORIGINATOR TO BIOSIMILAR SB5 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A REAL-LIFE SETTING

IBD (Posters)  et al.

RATES OF TREATMENT FAILURE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FIRST-LINE ADVANCED TREATMENTS
RATES OF TREATMENT FAILURE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FIRST-LINE ADVANCED TREATMENTS

IBD (Posters)  et al.

CLINICAL OUTCOMES IN FAMILIAL VERSUS SPORADIC INFLAMMATORY BOWEL DISEASE DIAGNOSED IN THE ERA OF BIOLOGICAL THERAPIES. PROSPECTIVE DATA FROM THE ENEIDA REGISTRY
CLINICAL OUTCOMES IN FAMILIAL VERSUS SPORADIC INFLAMMATORY BOWEL DISEASE DIAGNOSED IN THE ERA OF BIOLOGICAL THERAPIES. PROSPECTIVE DATA FROM THE ENEIDA REGISTRY

IBD (Posters)  et al.

Item 421 - 440 / 568
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
22
23 24 25 26 27 28 29